1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro]

What the CMS Formulary Data Shows for 1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro]

Per the CMS 2026 Part D formulary file, 1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro] (RxNorm concept RXCUI 2629981, generic name 1) appears on 28 distinct formulary files spanning 321 Medicare Part D plan offerings - 6.4% of enrollable Part D products, selective placement; verify formulary inclusion before enrolling. Tier placement ranges from Tier 1 to Tier 5, with a cross-plan average of Tier 4.6.

Real-world access to 1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro] depends on utilization management as much as tier placement: 92.9% of covering formularies require prior authorization. 0% require step therapy. 78.6% apply quantity limits.

Historical spending context from the CMS Medicare Part D Drug Spending Dashboard shows 27 Part D beneficiaries filled 1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro] in 2023, with total plan-and-beneficiary spending of $5,832,614 and an average per-beneficiary annual cost of $216,022.73. The plan-by-plan detail below lists exactly which PDP and MA-PD contracts carry 1 ML lanadelumab-flyo 150 MG/ML Prefilled Syringe [Takhzyro] today.